- Home
- SNY vs GSL Comparison
SNY vs GSL Comparison
Compare SNY & GSL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNY
- GSL
- Stock Information
- Founded
- SNY 1994
- GSL 2007
- Country
- SNY France
- GSL Greece
- Employees
- SNY N/A
- GSL N/A
- Industry
- SNY Biotechnology: Pharmaceutical Preparations
- GSL Marine Transportation
- Sector
- SNY Health Care
- GSL Consumer Discretionary
- Exchange
- SNY Nasdaq
- GSL Nasdaq
- Market Cap
- SNY 123.6B
- GSL N/A
- IPO Year
- SNY N/A
- GSL 2006
- Fundamental
- Price
- SNY $53.63
- GSL $21.23
- Analyst Decision
- SNY Buy
- GSL Strong Buy
- Analyst Count
- SNY 2
- GSL 1
- Target Price
- SNY $62.50
- GSL $29.00
- AVG Volume (30 Days)
- SNY 3.6M
- GSL 463.9K
- Earning Date
- SNY 04-24-2025
- GSL 05-15-2025
- Dividend Yield
- SNY 3.08%
- GSL 8.55%
- EPS Growth
- SNY 39.56
- GSL 17.78
- EPS
- SNY 5.45
- GSL 9.67
- Revenue
- SNY $48,817,552,946.00
- GSL $705,529,000.00
- Revenue This Year
- SNY $5.35
- GSL $1.84
- Revenue Next Year
- SNY $6.69
- GSL N/A
- P/E Ratio
- SNY $9.60
- GSL $2.19
- Revenue Growth
- SNY N/A
- GSL 5.82
- 52 Week Low
- SNY $45.80
- GSL $17.73
- 52 Week High
- SNY $60.12
- GSL $30.32
- Technical
- Relative Strength Index (RSI)
- SNY 50.20
- GSL 51.51
- Support Level
- SNY $50.46
- GSL $19.77
- Resistance Level
- SNY $51.64
- GSL $20.62
- Average True Range (ATR)
- SNY 1.60
- GSL 0.82
- MACD
- SNY 0.15
- GSL 0.19
- Stochastic Oscillator
- SNY 65.92
- GSL 96.92
About SNY Sanofi ADS
Sanofi develops and markets drugs with a concentration in vaccines, immunology, oncology, cardiovascular disease, diabetes, and over-the-counter treatments. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing about 30% of total sales, but profits are shared with Regeneron. Just over 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.